• Tue, August 8, 2023

David Nierengarten Maintained (ANAB) at Hold with Decreased Target to $26 on, Aug 8th, 2023

David Nierengarten of Wedbush, Maintained "AnaptysBio, Inc." (ANAB) at Hold with Decreased Target from $29 to $26 on, Aug 8th, 2023.

David has made no other calls on ANAB in the last 4 months.



There are 2 other peers that have a rating on ANAB. Out of the 2 peers that are also analyzing ANAB, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Anupam Rama of "JP Morgan" Upgraded from Sell to Hold and Decreased Target to $30 on, Monday, May 22nd, 2023


This is the rating of the analyst that currently disagrees with David


  • Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Increased Target to $45 on, Friday, May 12th, 2023